Metalabs
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Metalabs is a South Korean conglomerate listed on KOSPI that operates across fashion, business consulting, and healthcare distribution.
Its fashion arm licenses and distributes clothing brands through home-shopping and online channels, while also sourcing luxury goods from international brands for domestic distribution. Its consulting arm provides management, marketing, and operational services, everything except direct medical care, to clinics specialising in hair transplants and scalp treatment, and a separate healthcare unit distributes pharmaceuticals, medical devices, and consumables. Fashion is its largest revenue segment, followed by management consulting.
Summary is AI-generated and may contain errors · figures from DART filings
The consulting subsidiaries, including Meta S&C, Momo Labs, Momo Busan, Momo Daegu, and Momo Suwon, serve affiliated hospitals under formal management-consulting contracts, a structure common in Korea's non-covered medical services market.
Metalabs in five facts
What does Metalabs do?
Metalabs is a South Korean conglomerate listed on KOSPI that operates across fashion, business consulting, and healthcare distribution.
Where is Metalabs listed and in which sector?
Metalabs (Korean name: 메타랩스) trades under KRX code 090370 on KOSPI, the main board of the Korea Exchange. It is classified in the Consumer Discretionary sector, Consumer Durables.
How large is Metalabs?
Its market capitalisation was US$22.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Metalabs's latest annual revenue and operating profit?
For fiscal year 2025, Metalabs reported revenue of US$61.4M, an operating loss of US$5.5M and a net loss of US$9.3M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 112.0% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Merger decision (subsidiary)
Metalabs' subsidiary Meta S&C Co., Ltd. amended its August 3, 2026 merger-decision disclosure to push back the merger date and related schedule, under which Metalabs will absorb its wholly owned subsidiary Meta S&C as a small-scale merger at a 1:0 ratio with no new shares issued.
M&A · Aug 28 · 2 versions - [Amended] Material event report (merger)
Metalabs Co., Ltd. amended its merger report to push back the schedule for absorbing its wholly owned, no-new-shares subsidiary Meta S&C Co., Ltd., extending the creditor objection period to October 31, 2026 and moving the merger date to November 1, 2026 and the registration date to November 2, 2026.
M&A · Aug 28 · 2 versions - [Attachment amended] Material event report (merger)M&A · Aug 4
- Merger decision (subsidiary)
Metalabs' subsidiary MetaCare Co., Ltd. decided to absorb-merge its wholly owned subsidiary JK Medi Co., Ltd. in a small-scale merger with a 1.0000000:0.0000000 ratio and no new shares issued, with a merger date of 2026-10-01; MetaCare accounts for 79.20% of Metalabs' consolidated total assets.
M&A · Jul 29 - Decision to acquire shares/equity in another company (voluntary) (subsidiary)
Metalabs disclosed a subsidiary's acquisition of Tech Labs Co., Ltd., worth US$7.13M.
M&A · Jun 29 - Results of rights offering or equity-linked bond issuance (voluntary)Capital raise · Jun 17
- Decision to acquire shares/equity in another company (voluntary)
Metalabs disclosed an acquisition of Metacare, worth US$3.93M.
M&A · Jun 9 - Material event report (rights offering)
Metalabs disclosed a private placement (third-party allotment) to raise US$3.93M, about 18.8% of its market value.
Capital raise · Jun 9 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Metalabs reported consolidated results for FY2025: revenue of US$57M (+112.2% year on year), an operating loss of US$4.99M and a net loss of US$8.18M.
Earnings · Feb 26